PUBLIC COMPANY
saveGILEAD
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate caseThe California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.stat · 6h ago
- ‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spreeNot content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its me…fiercebiotech · 3d ago
- J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutJohnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.fiercebiotech · 4d ago
- AbCellera, Vertex partner on next-gen T-cell engagersThe deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.biopharma_dive · 5d ago
- Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months💊 Atea Pharmaceuticals’ hepatitis C pill matches Gilead’s Epclusa: The biotech said Tuesday that its combination therapy of bemnifosbuvir and ruzasvir (BEM/RZR) hit non-inferiority against Epclusa…endpoints · 5d ago
- GSK cost-cutting plan includes global layoffsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 5d ago
- Eli Lilly tops new biopharma ranking on launch success, development speedFlush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…fiercebiotech · 6d ago
- Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialAtea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.fiercebiotech · 6d ago
- AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failureAstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…biospace · 7d ago
- Argenx deepens immuno expertise with $2.2B Forte Biosciences buyThe star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.biospace · 7d ago
comments(0)
5-min edit window · permanent after that